Medicxi Ventures Management (Jersey) Ltd
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed April 15, 2024), Medicxi Ventures Management (Jersey) Ltd reported 5 stock positions worth $449.2 million. Its top holding was Centessa Pharmaceuticals (CNTA) at 50.2% of the portfolio, followed by Phathom Pharmaceuticals (PHAT, 17.6%) and Newamsterdam Pharma (NAMS, 15.1%). Compared with Q4 2023, it added to 1 and reduced 1. The biggest buy was Phathom Pharmaceuticals (PHAT, shares +98%) and the biggest sale Merus (MRUS, shares −27%).
- Most Recent 13F
- Q2 2026
- Location
- ST. HELIER, Y9
- CIK
- 0001715579
- Portfolio Value
- $449.2M (Q1 2024)
- SEC Filing
- 0000950123-24-003318 ↗ filed Apr 15, 2024
Holdings Value
Holdings 5 stocks · $449.2M
| CNTA Centessa Pharmaceuticals Ltd. | 50.22% | 19,963,157 | $225.6M | No change |
| PHAT Phathom Pharmaceuticals Inc. | 17.65% | 7,464,572 | $79.3M | Add +98.5% |
| NAMS Newamsterdam Pharma Co. NV | 15.11% | 2,869,565 | $67.9M | No change |
| MRUS Merus NV | 11.72% | 1,169,028 | $52.6M | Reduce -26.9% |
| AURA Aura Biosciences Inc. | 5.31% | 3,039,892 | $23.9M | No change |
Portfolio Sells Q4 2023 → Q1 2024
| MRUS Merus NV | Reduce -26.9% | 11.72% | −3.14 |
Portfolio Buys Q4 2023 → Q1 2024
| PHAT Phathom Pharmaceuticals Inc. | Add +98.5% | 17.65% | +6.06 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 3 | $177.4M | PHAT, NAMS, AURA |
| Q1 2026 | 4 | $981.8M | CNTA, NAMS, PHAT, AURA |
| Q4 2025 | 5 | $835.0M | CNTA, PHAT, NAMS, RAPT THERAPEUTICS INC, AURA |
| Q3 2025 | 5 | $744.4M | CNTA, PHAT, NAMS, RAPT THERAPEUTICS INC, AURA |
| Q2 2025 | 5 | $427.3M | CNTA, PHAT, NAMS, RAPT, AURA |
| Q1 2025 | 5 | $437.7M | CNTA, NAMS, PHAT, RAPT THERAPEUTICS INC, AURA |
| Q4 2024 | 5 | $529.0M | CNTA, NAMS, PHAT, RAPT THERAPEUTICS INC, AURA |
| Q3 2024 | 4 | $528.9M | CNTA, PHAT, NAMS, AURA |
| Q2 2024 | 4 | $335.3M | CNTA, PHAT, NAMS, AURA |
| Q1 2024 | 5 | $449.2M | CNTA, PHAT, NAMS, MRUS, AURA |